Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6393)	5/31/1998 10:19:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

Thanks for the kind words, George. I ducked into Yahoo! and read last couple of posts. Can't believe one person was recommending a reverse split. At the risk of being politically incorrect -- how do idiots like that get onto the Web? From his/her/its ballyhooing about the FDA not stopping the Neuprex Meningitis trial early, another clearly does not understand the review process for new medications, probably would not hurt him to take a walk through the annals of the FDA. Speaking of FDA, linked out on a Yahoo! post and eventually ended up here: fda.gov The CDER Handbook. Found New Drug Development and Review Process interesting. Actually found the whole site interesting. It links to all kinds of process flowcharts on the several different review processes the FDA is involved in.